“South Africa has introduced Lenacapavir, a long-acting injectable antiretroviral drug, into its public health system, strengthening its HIV prevention strategy. This rollout builds on years of progress with oral PrEP and positions the country at the forefront of global HIV prevention innovation.”
South Africa has once again demonstrated its leadership in global public health by introducing Lenacapavir, a revolutionary long-acting HIV prevention drug. Announced by Minister of Health Dr. Aaron Motsoaledi in July 2026, this rollout represents a decisive step in strengthening the country’s HIV prevention platform. With one of the world’s largest HIV epidemics, South Africa’s bold adoption of innovative prevention strategies has consistently set international benchmarks.
Background: HIV in South Africa
South Africa carries the largest HIV burden globally, with over 7.5 million people living with HIV. Despite significant progress in treatment and prevention, new infections remain a challenge, particularly among young women and key populations. The country’s public health system has long prioritized prevention, beginning with the rollout of oral pre-exposure prophylaxis (PrEP) in 2016. By 2021, oral PrEP had been successfully scaled across the public sector, even as many countries were still debating its feasibility.
What is Lenacapavir?
Lenacapavir is a long-acting injectable antiretroviral drug administered every six months. Unlike oral PrEP, which requires daily adherence, Lenacapavir offers a more convenient and discreet option. Clinical trials have shown it to be highly effective in preventing HIV transmission, particularly among populations with adherence challenges.
Why This Matters
- Improved adherence: Long-acting injectables reduce the burden of daily pill-taking.
- Accessibility: Integrated into South Africa’s primary healthcare system, ensuring nationwide reach.
- Global leadership: South Africa is among the first countries to adopt Lenacapavir at scale.
Implementation Strategy
The rollout is being integrated into existing HIV prevention services, including:
- Public clinics and hospitals already offering oral PrEP.
- Community-based programs targeting high-risk groups.
- Training for healthcare workers to administer and monitor the drug.
Challenges Ahead
Despite the promise, challenges remain:
- Cost and sustainability: Ensuring long-term affordability within the public health budget.
- Equity of access: Guaranteeing rural and marginalized communities benefit equally.
- Monitoring and evaluation: Tracking effectiveness and side effects in real-world settings.
Voices from the Field
Dr. Motsoaledi emphasized: “Lenacapavir represents the culmination of more than a decade of strategic leadership and health system strengthening. South Africa is proud to lead the world in HIV prevention innovation.”
Community health workers have welcomed the move, noting that injectable options may reduce stigma associated with daily pill-taking.
Global Context
South Africa’s rollout comes at a time when many countries are still piloting long-acting HIV prevention drugs. By scaling Lenacapavir nationally, South Africa sets a precedent for low- and middle-income countries, proving that innovation can be adopted beyond high-income settings.
Conclusion
The introduction of Lenacapavir is more than a medical milestone—it is a public health triumph. By combining scientific innovation with political will, South Africa continues to redefine what is possible in the fight against HIV. The rollout promises to reduce new infections, improve adherence, and inspire global action.
